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Abstract
Background: Treatment options for patients with metastatic colorectal cancer (mCRC) include anti-epithelial growth
factor therapies, which, in Europe, are indicated in patients with RAS wild-type tumours only and require prior mutation
testing of “hot-spot” codons in exons 2, 3 and 4 of KRAS and NRAS. The aim of this study was to evaluate
the implementation of RAS testing methods and estimate the RAS mutation prevalence in mCRC patients.
Methods: Overall, 194 pathology laboratories were invited to complete an online survey. Participating laboratories
were asked to provide information on their testing practices and aggregated RAS mutation data from 20 to 30 recently
tested patients with mCRC.
Results: A total of 96 (49.5 %) laboratories across 24 European countries completed the survey. All participants tested
KRAS exon 2, codons 12 and 13. Seventy (72.9 %) laboratories reported complete testing of all RAS hot-spot codons,
and three (3.1 %) reported only testing KRAS exon 2. Sixty-nine (71.9 %) laboratories reported testing >80 patients
yearly for RAS mutation status. Testing was typically performed within the reporting institution (93.8 %, n = 90), at
the request of a treating oncologist (89.5 %, n = 85); testing methodology varied by laboratory and by individual
codon tested. For laboratory RAS testing, turnaround times were ≤10 working days for the majority of institutions
(90.6 %, n = 87). The overall crude RAS mutation prevalence was 48.5 % (95 % confidence interval: 46.4–50.6) for
laboratories testing all RAS hot-spot codons. Prevalence estimates varied significantly by primary tumour location,
approximate number of patients tested yearly and indication given for RAS testing.
Conclusion: Our findings indicate a rapid uptake of RAS testing in the majority of European pathology
laboratories.
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Background
In recent decades, changing clinical practices, in con-
junction with the introduction of novel therapeutic
agents, have resulted in improved outcomes for patients
with metastatic colorectal cancer (mCRC) [1, 2]. Despite
this, the worldwide burden represented by colorectal
cancer (CRC), both in terms of incidence and mortality,
remains substantial [3, 4]. In Europe, CRC is now the
second most common malignancy. In 2012, approxi-
mately 447,000 new cases of CRC were diagnosed, with
an estimated 215,000 CRC-related deaths, representing
11.6 and 13.0 % of all cancer-related deaths in men and
women, respectively [5]. Approximately 20–25 % of pa-
tients with CRC will have evidence of metastatic disease
at the time of their diagnosis, and a further 40–50 % of
all patients with CRC will eventually develop metastases
during the course of their illness [6, 7].
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Monoclonal antibody (mAb) therapies that target the
epidermal growth factor receptor (EGFR), such as cetux-
imab and panitumumab, have been shown to improve
survival in patients with mCRC, both as monotherapies
and in combination with conventional chemotherapy
regimens [8–11]. Anti-EGFR mAbs have been found to
be ineffective in CRC patients with mutations affecting
the rat sarcoma viral oncogene homolog (RAS) gene
family, which includes the kirsten RAS (KRAS) and
neuroblastoma RAS (NRAS) oncogenes [10, 12, 13]. Mu-
tations affecting specific codons (so-called “hot-spot”
codons) in exons 2, 3 and 4 of the KRAS and NRAS
genes have been identified, which predict non-response
to anti-EGFR mAbs and allow the further malignant
proliferation of tumour cells, despite treatment [10, 14].
Initial research focused primarily on mutations of
KRAS exon 2, codons 12 and 13, which were originally
found to predict resistance to cetuximab and panitumu-
mab [13–15]. This led major oncology societies to
recommend that KRAS exon 2 mutation status should
be determined prior to anti-EGFR treatment [16, 17].
Therefore, treatment with anti-EGFR mAbs previously
only required confirmation of KRAS wild-type status;
however, in 2013, the European Medicines Agency
(EMA) revised the therapeutic indication, restricting it
to patients with RAS wild-type mCRC tumours only.
Consequently, testing of hot-spot codons in exons 2, 3
and 4 of KRAS and NRAS is now a requirement prior
to initiating treatment [18, 19]. This change was made
in response to growing evidence of the effects of RAS
family mutations in CRC. Key findings included effi-
cacy analyses of first-line anti-EGFR therapy, in com-
bination with chemotherapy, by RAS mutation status,
which demonstrated that additional RAS mutations
(other than KRAS exon 2) were predictive biomarkers
for non-response to treatment [10].
The revised EMA indication for the use of anti-EGFR
therapies highlights the need for consistent testing of the
RAS mutation status of patients with mCRC prior to
commencing treatment. The main aim of this retro-
spective survey was to assess the implementation of RAS
testing in Europe and to investigate whether there is any
variation in laboratory testing practices and turnaround
times. An additional aim was to estimate the RAS muta-
tion prevalence in patients with mCRC, according to
predefined clinical and demographic characteristics.
Methods
Participating institutions
Pathology laboratories from 26 European countries
currently or recently participating in the ongoing exter-
nal quality assurance (EQA) scheme of the European
Society of Pathology (ESP) for the testing of RAS muta-
tions in CRC were invited to take part in this study.
For each laboratory, a molecular biologist, pathologist
or other laboratory representative (e.g. technician) was
contacted directly by the study investigators and sup-
plied with a unique survey link in order to allow online
completion of the survey questionnaire and data collec-
tion form.
Survey composition and variables
The online survey was divided into two parts. The first
part included general questions about the characteristics
of the participating laboratory, clinical indications for
RAS mutation testing, DNA extraction method used and
RAS mutation testing methods for each codon tested. In
the second part of the survey, the participating labora-
tory was requested to provide aggregated data from ap-
proximately 20–30 of the most recent patients with
mCRC tested for RAS mutation status. This section of
the survey collected data on RAS mutation prevalence,
including a breakdown by codon, the site of the patient’s
primary tumour, the tissue sample site and the approxi-
mate turnaround time for RAS mutation testing. Turn-
around time was defined as the time from receiving the
request for RAS mutation testing to reporting of the re-
sult back to the requesting oncologist, grouped into 1–5,
6–10 and >10 working days.
The following codons were included in the online sur-
vey: KRAS and NRAS exon 2, codons 12 and 13; KRAS
and NRAS exon 3, codons 59 and 61; and KRAS and
NRAS exon 4, codons 117 and 146.
Prior to commencement of the study, the survey ques-
tions were tested on three pathologists/molecular biolo-
gists to assess the clarity of the survey questions and
amended accordingly.
Data collection
Survey results were collected in an anonymised fash-
ion to ensure that it would not be possible to link an-
swers to individual pathologists, molecular biologists
or pathology centres. Collection of aggregated patient
data from electronic pathology records ensured patient
anonymity and therefore individual patient consent
was not required. Each participating institution was
assigned a unique identifying code and communication
with the institutions was carried out by an independ-
ent third party. Non-responding institutions were
identified via any unused identification codes; the third
party at Radboud University Medical Centre reported
these codes to investigators at the University of Leuven,
who sent survey reminders to the institutions. Reminders
were sent to non-responders 4 weeks after their initial
invitation and again 2 weeks before the survey closed.
Data checks were conducted daily during the data
collection period to ensure data quality and address
any data-related issues.
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Statistical analysis
A descriptive analysis of the laboratory characteristics
and testing methods reported in the first part of the
survey was carried out.
The overall RAS mutation prevalence and prevalence
by patient characteristics and testing methods were cal-
culated from the aggregated patient data reported in the
second part of the survey. RAS mutation prevalence was
calculated for all patients and for the subgroup of
patients tested for all RAS hot-spot codons. The 95 %
confidence interval (CI) was calculated for each preva-
lence result using the Clopper–Pearson exact method.
Comparisons of RAS mutation prevalence according to
laboratory and patient characteristics were made using
the Pearson chi-squared test.
Results
Study participants
A total of 194 pathology laboratories at hospitals and in-
stitutions across 26 European countries were invited to
participate in the survey. Of the institutions contacted, 96
(49.5 %) laboratories in 24 of the countries satisfactorily
completed the online questionnaire between October and
December 2014. The average positive response rate, by
country, was 48.6 % of the invited laboratories with a
largely even distribution throughout Europe (Fig. 1).
Of the laboratories invited to participate in the study,
63 were listed as accredited on the website of their na-
tional accreditation body (NAB). In each country the
NAB is the organisation responsible for assessing adher-
ence to laboratory standards issued by the independent
International Organisation for Standardisation (e.g. CCKL
in the Netherlands and Cofrac in France). In total, 43.8 %
(n = 42) of the participating institutions were listed as
accredited. Additionally institutions that were accredited
were significantly more likely to respond to the survey;
a 66.7 % (n = 42) positive response rate was obtained
from the 63 accredited institutions, compared with a
41.2 % (n = 52) positive response rate from the 131
without NAB accreditation.
Fig. 1 Survey responses by country, showing number of participating institutions and invited institutions
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General hospitals and anti-cancer centres had a high
positive response rate of 51.1 % (n = 46) as did univer-
sities and university hospitals (54.2 %, n = 39); these
two broad categories made up the majority of the 96
respondents (47.9 % and 40.6 %, respectively). The
remaining invited laboratories were listed as industry
(n = 4) and private or private hospital (n = 28); these
categories had numerically lower positive response
rates, of 25.0 % (n = 1) and 35.7 % (n = 10), respectively,
but given the low numbers of institutions in these cat-
egories this was not significantly different from the
other categories. Invited institutions that had success-
fully passed their most recent ESP EQA scheme did
not have significantly higher positive response rates
than those institutions that had not passed (52.5 % and
34.4 %, respectively).
All 96 laboratories that responded completed the ini-
tial questionnaire part of the survey and 90 (93.8 %) of
these respondents provided aggregated patient data in
the second part of the survey. In total, aggregated data
were collected from 3,259 patients with CRC, of whom
the majority probably had metastatic disease. Of these
96 institutions, 71.9 % (n = 69) estimated that they
test more than 80 patients with mCRC per year, and
2.1 % (n = 2) estimated testing fewer than 20 patients
per year. A full description of the participating la-
boratories is given in Table 1.
RAS testing methods
The majority of participating institutions (89.5 %, n = 85)
reported that they carry out RAS testing only “On request
from an oncologist”, whereas 5.3 % (n = 5) of laboratories
reported testing “All patients with CRC” and 5.3 % (n = 5)
cited “Other” indications. RAS testing was most frequently
performed onsite within the reporting institution (93.8 %,
n = 90); 5.2 % (n = 5) of respondents reported a mixture of
both onsite and external (offsite) testing. A single respond-
ent reported only external testing of tumour samples for
RAS mutation status (Table 1).
Overall, 89.6 % (n = 86) of laboratories reported that
they use a minimum cut-off percentage of neoplastic
cells for histopathological assessment and subsequent
RAS testing. For the 86 laboratories using a cut-off
value, the reported minimum percentage of neoplastic
cells ranged from 1 to 50 %, with 18.8 % (n = 18) of the
laboratories reporting their minimum cut-off for testing
at <10 % and 70.8 % (n = 68) at ≥10 % (mean: 14.9 %;
median: 10.0 %) (Table 1).
There were five main DNA extraction methods used
by at least one of the laboratories surveyed, of which the
QIAamp DNA FFPE kit (Qiagen) (41.7 %), the Maxwell
16 system (Promega) (14.6 %) and the Cobas DNA
Sample Preparation kit (Roche) (12.5 %) were the most
commonly used (Table 1).
All 96 survey respondents reported testing for KRAS
exon 2 mutations. The implementation of testing for the
other RAS mutations (in KRAS exons 3 and 4, and
NRAS exons 2, 3 and 4) varied from 76.0 to 95.8 %. The
majority (72.9 %, n = 70) of the survey respondents re-
ported testing all 12 relevant codons. Three (3.1 %) par-
ticipants reported only testing KRAS exon 2. Full details
of the rate of RAS mutation testing by RAS codon are
shown in Table 2. Testing of extracted DNA for RAS
mutation status was assessed on a by-codon basis and
the responses divided into either those that used com-
mercially available CE-IVD kits or those using
sequencing-based methods. Overall no clear preference
in DNA testing method was observed, but CE-IVD kits
were most often used for testing KRAS exon 2, codons
12 and 13, by 47 and 48 % of respondents, respectively,
compared with 30 % of participants using sequencing-
Table 1 Description of participating pathology laboratories
Variable (n) Criterion Frequency %
Estimated number of patients
with mCRC tested per year
(n = 96)
>80 69 71.9
≤80 27 28.1
Reported indication for RAS
mutation testing (n = 95)
“On request from an
oncologist”
85 89.5
“All CRC patients
tested”
5 5.3
“Other”a 5 5.3
Location of RAS mutation
testing (n = 96)
Own institution 90 93.8
External 1 1.0
Own institution and
external
5 5.2
Minimum percentage of
neoplastic cells required
(n = 96)
No cut-off defined 10 10.4
<10 % 18 18.8
≥10 % 68 70.8
DNA extraction method
used (n = 96)
QIAamp DNA FFPE
kit (Qiagen)
40 41.7
Cobas DNA Sample
Preparation kit (Roche)
12 12.5
QIAamp DNA mini kit
(Qiagen)
7 7.3
Raw proteinase K
lysate
6 6.3
Maxwell 16 (Promega) 14 14.6
MagNA Pure (Roche) 1 1.0
Other 16 16.7
RAS mutations tested (n = 96) All codons tested 70 72.9
Not all codons tested 26 27.1
a“Other” reported indications for RAS testing were: “All stage III & IV CRC patients
are tested”, “In our hospital, all CRC patients are tested. Referrals from other
centres are tested on demand from the oncologist”, “Diagnostic combination”,
“On request from an oncologist as well as in known metastatic (M1) CRC
patients” and “Requested by oncologist and pathologist”. CRC colorectal cancer,
mCRC metastatic CRC
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based techniques for both codons. The same testing
method was used for all codons by 68.8 % of the respon-
dents. Pathology centres reported using the Therascreen
KRAS/NRAS pyro kit (Qiagen) most often, but with fre-
quencies varying from 8 to 14 % depending on the codon
being tested. The second most frequently used kit was the
KRAS/NRAS mutation detection kit (EntroGen). For those
laboratories using sequencing-based methods, the most
commonly used technique across all codons was dideoxy
(Sanger) sequencing (non-proprietary) ranging from 15 to
26 % of respondents depending on which codon was being
tested. The second and third most frequently used
sequencing-based methods were Ion AmpliSeq (Life Tech-
nologies) and Pyrosequencing (Qiagen), respectively, with
use by respondents reported as ranging from 7 to 9 % and
1 to 6 %, respectively, again depending on the tested codon.
Comprehensive details of the RAS testing methods
that were used by the participating laboratories for each
codon are shown in Table 2.
RAS mutation prevalence
Of the 3,259 patients included in the aggregated data,
3,244 (99.5 %), for whom RAS status was known and
documented, were included in the subsequent RAS muta-
tion prevalence analysis. The overall RAS mutation preva-
lence was 46.0 % (95 % CI: 44.3–47.7 %) for all included
patients. In a subgroup of 2,245 (68.9 %) patients for
whom all RAS hot-spot codons were tested, the total RAS
mutation prevalence was 48.5 % (95 % CI: 46.4–50.6 %).
All subsequent RAS mutation prevalence analyses and re-
sults described were restricted to this subgroup.
There was no significant variation in the rates of RAS
mutation prevalence by country (P = 0.461) for those
countries with at least three participating laboratories
(excluding any laboratories that did not test all codons).
Country-specific RAS mutation prevalence ranged from
40.0 % (95 % CI: 31.2–49.3 %) in Belgium to 52.1 %
(95 % CI: 44.7–59.5 %) in France.
The highest rates of RAS mutation prevalence for la-
boratories that tested all RAS hot-spot codons were re-
ported for KRAS exon 2, codons 12 and 13: 30.6 %
(95 % CI: 28.7–32.5 %) and 9.0 % (95 % CI: 7.9–10.3 %),
respectively. For the other codons, mutation rates
ranged from <0.1 to 2.8 %, with the exception of NRAS
exon 3, codon 59 and NRAS exon 4, codon 117, for
which no patients were identified with these RAS
Table 2 Frequency and percentage of laboratories using CE-IVD kits and sequencing-based methods by RAS codon
Exon KRAS exon 2 KRAS exon 3 KRAS exon 4 NRAS exon 2 NRAS exon 3 NRAS exon 4
Codon 12 13 59 61 117 146 12 13 59 61 117 146
Total laboratories testing, n (%) 96 (100) 96 (100) 78 (81) 92 (96) 86 (90) 87 (91) 90 (94) 90 (94) 79 (82) 90 (94) 73 (76) 80 (83)
CE-IVD kit (commercial kit), n (%) 45 (47) 46 (48) 26 (27) 40 (42) 31 (32) 31 (32) 35 (37) 35 (37) 27 (28) 35 (37) 26 (27) 32 (33)
Cobas KRAS mutation test (Roche) 11 (12) 11 (12) 3 (3) 11 (12) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1)
Therascreen KRAS/NRASpyro kit (Qiagen) 9 (9) 10 (10) 10 (10) 11 (12) 9 (9) 9 (9) 13 (14) 13 (14) 9 (9) 13 (14) 8 (8) 9 (9)
KRAS/NRAS mutation detection kit
(EntroGen)
10 (10) 9 (9) 3 (3) 10 (10) 9 (9) 9 (9) 10 (10) 10 (10) 4 (4) 10 (10) 5 (5) 10 (10)
Therascreen KRAS RGQPCR kit (Qiagen) 5 (5) 6 (6) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
KRAS/NRAS StripAssay (ViennaLab) 2 (2) 2 (2) 0 (0) 1 (1) 0 (0) 0 (0) 2 (2) 2 (2) 0 (0) 2 (2) 0 (0) 0 (0)
Anti-EGFR MoAb response
KRAS/NRAS (Diatech)
3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3)
Therascreen KRAS PCR kit (Qiagen) 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
KRAS/NRAS LightMix (TIB Molbiol) 1 (1) 1 (1) 0 (0) 0 (0) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3) 3 (3)
RAS extension pyro kit (Qiagen) 2 (2) 2 (2) 6 (6) 2 (2) 5 (5) 5 (5) 2 (2) 2 (2) 6 (6) 2 (2) 5 (5) 5 (5)
KRAS/NRAS gene mutation detection
kit (Diatech)
1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1)
PCR+sequencing or sequencing, n (%) 29 (30) 29 (30) 35 (37) 33 (34) 38 (40) 39 (41) 37 (39) 37 (39) 35 (37) 38 (40) 33 (34) 34 (35)
Dideoxy (Sanger) sequencing 14 (15) 14 (15) 20 (21) 18 (19) 24 (25) 25 (26) 22 (23) 22 (23) 21 (22) 22 (23) 25 (26) 25 (26)
Pyrosequencing (Qiagen) 5 (5) 5 (5) 5 (5) 5 (5) 4 (4) 4 (4) 5 (5) 5 (5) 4 (4) 6 (6) 1 (1) 2 (2)
Ion AmpliSeq - Ion Torrent
(Life Technologies)
9 (9) 9 (9) 9 (9) 9 (9) 9 (9) 9 (9) 9 (9) 9 (9) 9 (9) 9 (9) 7 (7) 7 (7)
The TruSeq Amplicon - Cancer Panel
(Illumina)
1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 0 (0) 0 (0)
Other methods, n (%) 16 (17) 15 (16) 10 (10) 10 (10) 10 (10) 9 (9) 12 (13) 12 (13) 11 (11) 11 (11) 8 (8) 8 (8)
Multiple methods, n (%) 6 (6) 6 (6) 7 (7) 9 (9) 7 (7) 8 (8) 6 (6) 6 (6) 6 (6) 6 (6) 6 (6) 6 (6)
PCR polymerase chain reaction
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mutations (Fig. 2). In this cohort, mutations affecting
KRAS exon 2, codons 12 and 13 accounted for 62 and
18 %, respectively, of all RAS mutations identified.
For the 1,393 (42.7 %) patients with a documented
primary CRC tumour site, RAS mutation prevalence
was found to vary significantly by location when com-
paring right and left colon primary tumours: 54.6 %
(95 % CI: 50.2–59.0 %) and 46.4 % (95 % CI: 41.6–
51.2 %), respectively (P = 0.012). However, when com-
paring right and left colon cancers with rectal tumours,
for which the RAS mutation prevalence was 51.0 %
(95 % CI: 46.3–55.7 %), there was no overall significant
difference (P = 0.043). There was also no significant dif-
ference in RAS mutation prevalence according to the
type of tissue sample used for RAS testing, categorised
as either primary or secondary (metastatic) tumour
tissue (Table 3).
The RAS mutation prevalence calculated for laborator-
ies that estimated testing >80 patients with mCRC for
RAS status each year was significantly higher than for la-
boratories that estimated testing ≤80 patients: 49.7 %
(95 % CI: 47.3–52.0 %) compared with 44.8 % (95 % CI:
40.5–49.0 %). RAS mutation prevalence also varied sig-
nificantly according to the indication given for testing:
60.7 % (95 % CI: 49.5–71.2 %) for “All CRC patients are
tested” compared with 48.6 % (95 % CI: 46.4–50.8 %) for
“On request from an oncologist”, and 43.2 % (95 % CI:
35.1–51.6 %) for “Other” indications (Table 3).
There were no significant differences in RAS mutation
prevalence when comparing onsite with offsite testing,
DNA extraction method used and whether or not labora-
tories used a cut-off for the minimum percentage of neo-
plastic cells, or if the cut-off was <10 % or ≥10 % (Table 3).
RAS testing turnaround time
Overall, for the 3,171 (97.3 %) patients with CRC for
whom turnaround time was documented, results were
reported back to the requesting physician in ≤5 working
days after the test was requested in nearly half of the
cases (47.1 %). Only 9.2 % of RAS testing results had a
reported turnaround time of >10 working days.
Reported turnaround times varied for each country,
with Switzerland, Austria and Denmark having the
greatest proportions of patients with a turnaround time
of ≤5 working days: 85.3 %, 75.6 % and 64.2 %, respect-
ively (P < 0.001). By contrast, Turkey, the Czech Republic
and Sweden had the greatest proportions of patients
with a documented turnaround time of >5 working days:
100 %, 95.6 % and 92.7 %, respectively (P < 0.001).
Laboratories that estimated the number of patients
with mCRC tested for RAS mutation status per year as
>80 had longer turnaround times compared with those
that estimated testing ≤80 patients per year: 40.0 % vs.
61.0 % in ≤5 days, respectively (P < 0.001). A comparison
of turnaround times for patients according to which
RAS codons had been tested, demonstrated that turn-
around times were ≤5 days for 44.4 % of those tested for
all codons and 54.1 % for patients with only partial RAS
mutation testing (P < 0.001). Laboratories using the same
RAS mutation testing method for all codons being tested
had shorter turnaround times than those in which more
than one method was used: 50.1 % vs. 32.7 % in ≤5 days,
respectively (P < 0.001).
Reported turnaround times also varied according to
the clinical indication given for RAS testing. For patients
tested at the request of an oncologist, and patients tested
at institutions that test all patients with CRC, the
Fig. 2 RAS mutation prevalence by codon for tumour samples tested for all RAS codons (n = 2,245)
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proportions with a turnaround time of ≤5 days were
46.2 and 32.1 %, respectively. For patients tested at insti-
tutions that reported other indications for RAS testing,
the proportion with a turnaround time of ≤5 days was
74.2 %. Laboratories that reported carrying out RAS test-
ing at their own institution had shorter turnaround
times compared with those that reported using a mix-
ture of onsite and external testing: 48.8 % vs. 11.7 % of
results were reported in ≤5 days, respectively (P < 0.001).
The aggregated patient data by turnaround time are
shown in detail in Table 4.
Discussion
Recent revisions to the prescribing guidelines for anti-
EGFR mAbs require RAS genotyping in patients with
mCRC prior to the initiation of therapy. These revisions
have necessitated a change in the management and test-
ing of patients with mCRC, and thus highlight the need
for investigation into RAS mutation testing practices and
their variability within Europe.
Here we report results from an online survey of 96
pathology laboratories from 24 European countries. All
96 laboratories reported testing for KRAS exon 2 muta-
tions, and the majority (72.9 %) reported testing all the
required RAS codons as standard. The findings of this
survey confirm the increase in implementation of RAS
mutation testing that has been reported in recent studies
both within and outside of Europe [20, 21]. Results of
the 2013 ESP Colon EQA scheme, which included 131
laboratories from 30 different countries, showed that
49.3 % of the participating laboratories had implemented
RAS testing for all hot-spot codons [20]. A number of
Table 3 RAS mutation prevalence estimates for tumour samples tested for all RAS codons
RAS mutation status RAS mutation prevalence
Variable (n) Criterion Wild-type Mutated (%) 95 % CI P-value
Overall RAS mutation prevalence (n = 2,245) Patients with all codons tested only 1,156 1,089 48.5 (46.4–50.6)
Location of primary tumoura (n = 1,393) Right colon (proximal to splenic flexure) 232 279 54.6 (50.2–59.0)
Left colon (distal to splenic flexure) 230 199 46.4 (41.6–51.2) 0.012b
Rectum 222 231 51.0 (46.3–55.7) 0.043c
Tissue type isolateda (n = 1,669) Primary tumour 651 653 50.1 (47.3–52.8)
Metastatic site 184 181 49.6 (44.3–54.8) 0.869
Number of patients tested per year
(n = 2,093)
>80 861 850 49.7 (47.3–52.0)
≤80 295 239 44.8 (40.5–49.0) <0.001
Indication for testing (n = 2,215) “On request from an oncologist” 1,019 964 48.6 (46.4–50.8)
“All patients with CRC tested” 33 51 60.7 (49.5–71.2)
“Other” 84 64 43.2 (35.1–51.6) 0.036d
Location of testing (n = 2,245) Own institution 1,117 1,054 48.5 (46.4–50.7)
Own institution and external 39 35 47.3 (35.6–59.3) 0.832
Minimum percentage of neoplastic cells
(n = 2,445)
No cut-off defined 75 78 51.0 (42.8–59.1)
Cut-off defined 1,081 1,011 48.3 (46.2–50.5) 0.526
Cut-off percentage of neoplastic cells
(n = 2,092)
Cut-off <10 % 177 137 43.6 (38.1–49.3)
Cut-off ≥10 % 904 874 49.2 (46.8–51.5) 0.071
DNA extraction method used (n = 2,245) QIAamp DNA FFPE kit (Qiagen) 475 463 49.4 (46.1–52.6)
Cobas DNA Sample Preparation kit (Roche) 75 73 49.3 (41.0–57.7)
QIAamp DNA mini kit (Qiagen) 79 56 41.5 (33.1–50.3)
Raw proteinase K lysate 97 79 44.9 (37.4–52.6)
Maxwell 16 (Promega) 192 178 48.1 (42.9–53.3)
MagNAPure (Roche) 15 19 55.9 (37.9–72.8)
Other 223 221 49.8 (45.0–54.5) 0.550
aOnly includes wild-type and mutated results. Patients with unknown/unavailable RAS mutation status have been excluded
bComparison of RAS mutation prevalence between right colon and left colon primary tumours only, excluding data from rectal tumours
cComparison of RAS mutation prevalence between right colon, left colon and rectal primary tumours
dFor the purposes of comparing RAS mutation prevalence, patients reported as having been tested due to “Other” indications have been grouped together
Of note, patients reported in aggregated data sample may have had RAS-family mutations affecting more than one oncogene
CRC colorectal cancer, CI confidence interval
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factors may have contributed to the disparity in the pro-
portions of laboratories reportedly testing all KRAS and
NRAS codons between this survey and the 2013 EQA
scheme; in particular, the latter was initiated very soon
after the revisions to the EMA indications for anti-EGFR
mAbs, and included participants from outside of Europe.
Fewer than half of the participating laboratories were
accredited by a NAB, although the response rate was higher
among these institutions than among non-accredited la-
boratories. This is in agreement with reports from the ESP
EQA scheme, which observed that few laboratories partici-
pating have been accredited according to a well-known
international standard [20]. This highlights the need
for increased efforts to encourage more laboratories to
seek accreditation.
In the present survey we found that the majority of
laboratories (71.9 %) test >80 patients a year for RAS
mutation status, with testing typically carried out at the
requesting institution (93.8 %) and at the request of an
oncologist (89.5 %). Only 5.3 % of laboratories routinely
test all their patients with CRC for RAS mutation sta-
tus; however, this means that the information is imme-
diately available to the treating oncologists at these
institutions prior to considering treatment with anti-
EGFR mAbs. RAS mutation testing methodologies vary
considerably among pathology laboratories and accord-
ing to the codon being tested. Overall the reported use
of different categories of testing methods was broadly
similar to that of previous ESP EQA schemes [20, 22].
Our findings not only confirm that dideoxy sequencing
remains the single most commonly used method, but
also that the use of next-generation sequencing tech-
niques and of commercially available kits, such as the
Cobas KRAS mutation test (Roche) and the Therasc-
reen KRAS/NRAS pyro kit, has remained consistent
over the last 3 years. The high degree of variability in
RAS testing methods used among different laboratories
underscores the need for EQA schemes to assess and
Table 4 Turnaround time for RAS testing results by country and testing practices
Turnaround time (working days)
Variable (n) Criterion ≤5 (%) 6–10 (%) >10 (%)
n = 3,191 1,511 (47.4) 1,389 (43.5) 291 (9.1)
Countrya n = 3,171 Austria (n = 201) 152 (75.6) 49 (24.4) 0 (0.0)
Belgium (n = 240) 70 (29.2) 93 (38.8) 77 (32.1)
Czech Republic (n = 90) 4 (4.4) 65 (72.2) 21 (23.3)
Denmark (n = 120) 77 (64.2) 39 (32.5) 4 (3.3)
France (n = 238) 60 (25.2) 111 (46.6) 67 (28.2)
Italy (n = 276) 109 (39.5) 149 (54.0) 18 (6.5)
Netherlands (n = 457) 259 (56.7) 194 (42.5) 4 (0.9)
Norway (n = 74) 29 (39.2) 27 (36.5) 18 (24.3)
Poland (n = 80) 43 (53.8) 32 (40.0) 5 (6.3)
Spain (n = 192) 55 (28.7) 134 (69.8) 3 (1.6)
Sweden (n = 82) 6 (7.3) 72 (87.8) 4 (4.9)
Switzerland (n = 415) 354 (85.3) 56 (13.5) 5 (1.2)
Turkey (n = 90) 0 (0.0) 66 (73.3) 24 (26.7)
Number of patients tested per year (n = 3,191) >80 828 (40.0) 1,022 (49.3) 222 (10.7)
≤80 683 (61.0) 367 (32.8) 69 (6.2)
RAS mutations tested (n = 3,191) All codons tested 983 (44.4) 1,102 (49.8) 130 (5.9)
Not all codons tested 528 (54.1) 287 (29.4) 161 (16.5)
Same testing method for all codons (n = 3,191) Yes 1,345 (50.1) 1,142 (42.6) 197 (7.3)
No 166 (32.7) 247 (48.7) 94 (18.5)
Indication for RAS testing (n = 3,161) “On request from an oncologist” 1,325 (46.2) 1,288 (44.9) 258 (9.0)
“All CRC patients tested” 36 (32.1) 56 (50.0) 20 (17.9)
“Other” 132 (74.2) 33 (18.5) 13 (7.3)
Location of testing (n = 3,191) Own institution 1,496 (48.8) 1,343 (43.9) 224 (7.3)
Own institution and external 15 (11.7) 46 (35.9) 67 (52.3)
aCountries with fewer than three laboratories have been excluded from this table
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ensure the ongoing accuracy and precision of RAS
mutation testing.
The overall crude RAS mutation prevalence was cal-
culated as 48.5 % (95 % CI: 46.4–50.6 %) for patients
tested for all relevant RAS codons. The calculated over-
all RAS mutation prevalence in this study was consist-
ent with findings from sequenced CRC tumours in the
2012 TCGA database (49 %) and from a recent study of
the reproducibility of RAS testing among pathology
centres in the Netherlands (47.6 %), but was slightly
lower than in a recently published pooled analysis of
clinical trials of anti-EGFR therapy in patients with
mCRC, which showed an overall RAS mutation preva-
lence of 55.9 % (95 % CI: 53.9–57.9 %) [23–25]. RAS
mutation prevalence estimates varied significantly by
country, approximate number of patients tested per
year and the indication for RAS testing and between
left- and right-sided tumours. Previous research has
indicated that RAS mutated tumours occur more fre-
quently in the ascending (right) colon than the de-
scending (left) colon [26–28]. The results from the
present survey support this conclusion, showing that
the prevalence of RAS mutations was higher in patients
with right-sided primary tumours compared with those
with left-sided primary tumours. The RAS mutation
prevalence observed at centres that routinely tested all
patients with CRC appeared unusually high when com-
pared with the overall prevalence rate in this study.
However, it is important to note that the sample size
for this subgroup was small (five pathology centres pro-
viding data for 84 patients). Therefore, this result needs
to be interpreted with caution.
Turnaround time was found to be ≤10 working days,
which is recommended for routine clinical practice for the
majority of patients (90.8 %). However, nearly half (47.1 %)
of the patients assessed had their result reported in
≤5 days. It should be noted that, as turnaround time was
defined as the time from the laboratory receiving the re-
quest to reporting of the result back to the requesting
physician, the real time may be longer in some cases, for
example due to transportation of tissue blocks from one
laboratory to another. Factors that prolonged turnaround
time were testing of >80 patients a year (which may be
due to overburdening of laboratories), testing of all RAS
codons and external testing of some patient samples.
When considering therapy with anti-EGFR mAbs it is im-
portant that the RAS testing results are made available to
the requesting oncologist as quickly as possible as patients
with mCRC can deteriorate rapidly, over a period of
weeks, and need urgent, effective, treatment decisions.
Although the overall response rate (49.5 %) for this
study was relatively high for an online survey, it may not
be fully representative of European laboratory practices.
The survey was intended to be completed by the
molecular biologist responsible for molecular diagnostics
at each of the participating laboratories, however this
could not be verified from the survey results, and it is
possible that in some instances it was completed by a
technician or another laboratory representative.
Determining RAS mutation prevalence and variation
on the basis of aggregated patient CRC data is a po-
tential limitation of this study, as it was not possible
to account for the influence of non-reported patient-
specific factors and clinical variables that may have
influenced the results. Also, because certain clinical
findings are often omitted from pathology records,
data for some of the categories were not available for
a large proportion of the patients. Finally, recent clin-
ical guidelines have recommended the use of resected
tissues for RAS mutation testing, where possible, ra-
ther than biopsy specimens [29], but information
about the type of tissue used could not be captured
in the present study. Furthermore, although it is rea-
sonable to assume that most samples have been taken
from patients with mCRC, it is likely that a small
proportion of tumour samples will have been col-
lected (by laboratories routinely testing all CRC pa-
tients) from patients who did not have any evidence
of metastases at the time. Therefore the data pre-
sented may not exclusively represent a population of
mCRC patients. However, it has been shown previ-
ously that there is a high concordance of KRAS exon
2 mutation status between primary colorectal tumours
and their corresponding liver metastases [30].
Conclusions
The findings from this study show that implementation
of full RAS testing, for exons 2, 3 and 4 of KRAS and
NRAS, is high but not yet universal, with nearly three-
quarters of the participating laboratories reporting full
testing of the relevant RAS oncogenes. This would seem
to reflect an overall upward trend in the implementation
of full RAS testing, with the rate documented in this
study considerably higher than the 49.3 % of laboratories
testing all codons as reported in the results from the
2013 ESP Colon EQA scheme [20]. A small minority of
the respondents (n = 3) reported that they still only test
KRAS exon 2 (the previous EMA indication for the use
of anti-EGFR mAbs).
This is the first study to capture turnaround time
for RAS testing, and our findings showed that the
turnaround time for results is ≤5 working days for al-
most half of the laboratories that participated. Further
observational studies will be needed to clarify whether
the implementation and standardisation of RAS muta-
tion testing changes significantly in the near future.
However, these findings, showing current variation of
RAS testing practices, contribute to the developing
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body of evidence relating to the prevalence of RAS
mutations and create awareness of factors that can
affect turnaround time and accurate detection of all
RAS mutations.
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